News
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
25 Apr 24
Biotech, Large Cap, News, Health Care, Top Stories, General
Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity Investment
25 Apr 24
News, Contracts
Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCO
24 Apr 24
Biotech, News, General
Regeneron To Present New And Updated Data Across Its Genetic Medicines Portfolio At ASGCT Annual Conference
22 Apr 24
News
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
18 Apr 24
News, Markets, Trading Ideas
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
17 Apr 24
Analyst Color, Biotech, Equities, Large Cap, News, Health Care, Reiteration, Analyst Ratings, Trading Ideas, General
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
17 Apr 24
News, Trading Ideas
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price Target
15 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
12 Apr 24
Analyst Ratings
B of A Securities Maintains Underperform on Regeneron Pharmaceuticals, Raises Price Target to $720
12 Apr 24
News, Price Target, Analyst Ratings
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
11 Apr 24
Biotech, Large Cap, News, Health Care, Legal, Top Stories, General
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
11 Apr 24
Options, Markets
RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1189 Price Target
9 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Reported Sunday, Regeneron Pharmaceuticals Presented Pivotal Data On Linvoseltamab At AACR 2024, Reinforcing A High Response Rate That Deepens Over Time In Patients With Heavily Pre-Treated Multiple Myeloma
8 Apr 24
News
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Maintains $1135 Price Target
3 Apr 24
News, Price Target, Analyst Ratings
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
1 Apr 24
News, Trading Ideas
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
28 Mar 24
Options, Markets
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
26 Mar 24
Analyst Ratings
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Maintains $1135 Price Target
26 Mar 24
News, Price Target, Analyst Ratings
Press releases
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
22 Apr 24
Press Releases
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
18 Apr 24
News, Legal, Press Releases
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
17 Apr 24
News, Legal, Press Releases
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
17 Apr 24
Press Releases
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
11 Apr 24
News, Legal, Press Releases
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
7 Apr 24
News, Analyst Ratings, Press Releases
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
1 Apr 24
News, Press Releases
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
28 Mar 24
News, Press Releases
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24
News, Press Releases
Regeneron Provides Update on Biologics License Application for Odronextamab
25 Mar 24
Health Care, Press Releases
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
22 Mar 24
Press Releases
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
22 Mar 24
News, Press Releases
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
12 Mar 24
Press Releases
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
11 Mar 24
Health Care, Press Releases
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
8 Mar 24
Health Care, Press Releases, General
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
23 Feb 24
Press Releases, General
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
23 Feb 24
News, Press Releases
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
21 Feb 24
Health Care, Press Releases, General
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
16 Feb 24
News, Press Releases
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16 Feb 24
Health Care, Press Releases, General